Separation Of Immune Complex From Unbound Antigen Or Antibody Patents (Class 436/538)
-
Patent number: 4717654Abstract: Drug-induced thrombocytopenia can be detected via the use of an enzyme-linked immunospecific assay.Type: GrantFiled: June 19, 1984Date of Patent: January 5, 1988Assignee: Akzo N.V.Inventors: Kenneth V. Savoca, Valerie E. Macdonald
-
Patent number: 4711840Abstract: Immunoassay methods and compositions are disclosed for the detection of one or more analytes in fluid samples. The disclosure provides conjugates of analytes or reactants with polymerizable organic monomers. Specific binding reactions between reactants are detected by means of reporter/reactant conjugates. Free and specifically-bound reporter/reactant conjugates are separated by a polymerization reaction which renders the polymerized monomers insoluble.Type: GrantFiled: November 7, 1984Date of Patent: December 8, 1987Assignee: Genetic Systems CorporationInventors: Robert C. Nowinski, Allan S. Hoffman
-
Patent number: 4692416Abstract: The invention relates to monoclonal anti-idiotypic antibodies to human anti-DNA antibodies. Monoclonal, anti-idiotypic antibodies are produced using hybridoma technology. The antibodies are used as diagnostic reagents in methods to determine the presence of anti-native DNA antibodies in serum from patients suspected of having systemic lupus erythematosus.Type: GrantFiled: November 16, 1983Date of Patent: September 8, 1987Assignee: Yeshiva UniversityInventor: Betty A. Diamond
-
Patent number: 4690905Abstract: The invention relates to monoclonal anti-idiotypic antibodies to human anti-DNA antibodies. Monoclonal, anti-idiotypic antibodies are produced using hybridoma technology. The antibodies are used as diagnostic reagents in methods to determine the presence of anti-native DNA antibodies in serum from patients suspected of having systemic lupus erythematosus, and as therapeutic reagents in methods to remove the anti-native DNA antibodies from the serum of patients with systemic lupus erythematosus.Type: GrantFiled: November 30, 1983Date of Patent: September 1, 1987Assignee: Albert Einstein College of Medicine of Yeshiva University, a division of Yeshiva UniversityInventor: Betty A. Diamond
-
Patent number: 4687733Abstract: The invention relates to a method of testing for the presence of cancer. An antibody is produced which contains antibodies specific to a modified nucleoside component. The antibody is admixed with a body fluid drawn from a subject mammal. An immunoassay is performed on the admixture to quantify an amount of cancer associated nucleoside present in the fluid and reactive with the antibody.Type: GrantFiled: January 30, 1984Date of Patent: August 18, 1987Assignee: Ohio State UniversityInventors: Ronald W. Trewyn, Steven M. D'Ambrosio
-
Patent number: 4687636Abstract: This invention relates to the use of differential separative properties and modified assay containers in improving the convenience of separative scintillation proximity assay (SSPA) and extending its range of practical application.Type: GrantFiled: January 3, 1984Date of Patent: August 18, 1987Inventor: Hiram Hart
-
Patent number: 4681782Abstract: An immunoassay of a specimen of a serum or the like to determine the composition of immune complexes, includes producing on a plastic base a layer of a non-proteinaceous, non-ionic polymer which will adhere to the plastic base and has the capability of adsorbing immune complexes of the specimen, placing a specimen on the layer and treating the layer to produce an indication of the composition of the immune complexes. The polymer may be polyethylene glycol, dextran, polyvinyl chloride, a polymeric polyol or an adduct of polyethylene glycol or mixtures thereof. Washing with conventional solutions, addition of monoclonal and/or polyclonal antibodies coupled with an enzyme and addition of a substrate reactive therewith to determine the antigen component, are similar to the ELISA test, with color measurement as by spectrophotometer. Or, the addition of anti IgG-I.sup.125 and measurement by a scintillation counter may be used. Addition of IgG, IgA, IgE, IgG.sub.Type: GrantFiled: October 3, 1983Date of Patent: July 21, 1987Assignee: Biostar Medical Products, Inc.Inventor: Adil N. Ozkan
-
Patent number: 4670383Abstract: This invention describes a process for immuno-chemical quantitative determination of immunologically active substances. The method involves a first incubation of a sample containing the active substance with a labelled binder, which contains an antibody or antibody fragment. After complexing has taken place, solid phase bound active substance identical to the substance being quantitatively determined is added. The solid phase bound substance binds with free binder, and the solid and liquid phases are separated. A second antibody which is specific either to antibody or the solid phase antibody-substance complex is then added to the liquid phase. This second antibody is non cross-reactive with individual complex components. The amount of labelled first antibody bound to second antibody is then determined.Type: GrantFiled: September 13, 1985Date of Patent: June 2, 1987Assignee: Boehringer Mannheim GmbHInventors: Manfred Baier, Helmut Jering, Sigmar Klose
-
Patent number: 4666866Abstract: Assay for a hapten or antigen wherein supported hapten or antigen is used to separate "bound" and "free" fractions. The sensitivity of the assay is increased.Type: GrantFiled: April 19, 1983Date of Patent: May 19, 1987Inventor: Gary H. Krauth
-
Patent number: 4656251Abstract: A method for the rapid separation of Dirofilaria immitis immune complexes in a sample of blood or bodily fluid from an animal infected with Dirofilaria immitis preparatory to assaying for the presence of circulating parasite antigens of Dirofilaria immitis involves the steps of (a) lowering the pH of the sample to below 3.0 to effect the separation of circulating parasite antigens of Dirofilaria immitis from antibodies therefor in the sample; (b) heating the sample to a temperature within the range of approximately 56.degree. C. to 90.degree. C. for a sufficient period of time to denature the separated antibodies; and (c) increasing the pH of the resulting sample to within the range of approximately 7 to 8 to produce a sample which may be assayed for the presence of circulating parasite antigens of Dirofilaria immitis without interference from the separated antibodies.Type: GrantFiled: January 28, 1985Date of Patent: April 7, 1987Assignee: Mallinckrodt, Inc.Inventor: Larry D. Mosier
-
Patent number: 4656143Abstract: A heterogeneous binding assay in which a liquid component and a granular particulate solid phase are incubated together for a predetermined period of time. To prevent unwanted unit gravity sedimentation of the granular particulate solid phase during incubation the density of the liquid component is controlled such that it is substantially equal to the density of the granular particulate solid phase, thus preventing sedimentation. The density may be controlled by adding a density modifying medium such as a colloidal suspension of silica particles coated with polyvinylpyrrolidine. After incubation, the density of the liquid component may be reduced allowing unit gravity sedimentation and hence separation of the solid phase from the liquid component. The assay is particularly applicable to immunoassay (for example radioimmunoassay and immunoradiometric assay). Immunoradiometric assays for human growth hormone, thyroid stimulating hormone and alphafetoprotein are described.Type: GrantFiled: March 15, 1984Date of Patent: April 7, 1987Inventors: Terence S. Baker, Stephen R. Abbott, John G. Simpson, John F. Wright, Michael J. Powell
-
Patent number: 4652533Abstract: A method is provided for solid phase immunoassay for quantitation of antigen, hapten or antibody analyte in liquid sample and alternatively for quantitation of analyte occuring on or attached to cells or other particulate material in a liquid sample. The solid phase is suspended for at least the initial reactions and is subsequently concentrated by microfiltration to a volume substantially less than the sample volume. Luminescence of substantially the entire label on the concentrated solid phase is measured.Type: GrantFiled: April 28, 1983Date of Patent: March 24, 1987Assignee: Pandex Laboratories, Inc.Inventor: Michael E. Jolley
-
Patent number: 4652532Abstract: A biochemical method of assaying for ligand molecules in fluids based on the specific interaction of a ligand and a ligand-recognition molecule that binds the ligand wherein a free radical forming group is covalently coupled to label either a ligand sought to be assayed or the ligand recognition molecule or is internally generated from the ligand or ligand recognition molecule, and directly or indirectly assaying for the ligand.Type: GrantFiled: December 24, 1984Date of Patent: March 24, 1987Inventors: James D. Bain, Billy L. Lasley
-
Patent number: 4645747Abstract: The present invention relates to a simple and accurate method to be applied in immunoassay technique for separating the free ligand from the antibody-bound ligand.The method involves the use of a solvent extraction operation which at equilibrium provides the formation of two distinct phases the free- and bound-fraction. The solvent to be utilized should be slightly water miscible or completely water immiscible, having the property of marked selective extraction power toward the gamma-labelled constituent to be determined. The method is applicable in a liquid-liquid system, a solid-liquid system and solid-solid system.The method is useful for radioimmunoassay, free radical assay or metallo-immunoassay, being most versatile having also the advantage that as a result of the free ligand being extracted into the solvent, the determination of the quantity of gamma-labelled substance in the free and/or bound fraction compares very favorably with the known prior art methods in immunoassays.Type: GrantFiled: February 28, 1983Date of Patent: February 24, 1987Assignee: Technion Research & Development Foundation, Ltd.Inventors: Michael Cais, Moshe Shimoni, Abraham Baniel
-
Patent number: 4642284Abstract: A method and system for detecting and preferably measuring the presence of an activated complement complex in a sample is discussed. The presence of such an activated complex is indicative of complement pathway activation and includes a first complement component and a second complement component. The method uses a first binding agent specific to the first complement component and a second binding agent specific to the second complement component which when bound with the complex forms an aggregate. The second specific binding agent includes a label whose presence is used to detect and measure the amount of aggregate and therefore activated complex in a sample. An assay system and aggregate for use in an assay system are also discussed.Type: GrantFiled: June 13, 1983Date of Patent: February 10, 1987Assignee: Scripps Clinic and Research FoundationInventors: Neil Cooper, James T. Mayes
-
Patent number: 4628027Abstract: Collagen profiles of human body tissues and fluids, i.e., the types of distinct connective tissue proteins present, their distribution in human body tissues and fluids, and the concentration ratios among distinct types, are subject to change during certain pathological conditions and during therapeutic regimens for the treatment of such conditions. These changes in collagen profiles can be detected by immunohistological, immunocytological and immunoserological techniques. In vitro diagnostic methods employing monoclonal antibodies specific for connective tissue proteins are provided which can be used for monitoring the results of therapeutic measures taken against inflammatory diseases, fibrotic diseases and cancer and for detecting or following the pathogenesis of such diseases.Type: GrantFiled: April 18, 1984Date of Patent: December 9, 1986Assignees: Molecular Engineering Associates, Ltd., The Board of Trustees of the Universtiy of AlabamaInventor: Steffen Gay
-
Patent number: 4628037Abstract: A process is provided for the preparation of magnetic particles to which a wide variety of molecules may be coupled. The magnetic particles can be dispersed in aqueous media without rapid settling and conveniently reclaimed from media with a magnetic field. Preferred particles do not become magnetic after application of a magnetic field and can be redispersed and reused. The magnetic particles are useful in biological systems involving separations.Type: GrantFiled: June 13, 1985Date of Patent: December 9, 1986Assignee: Advanced Magnetics, Inc.Inventors: Mark S. Chagnon, Ernest V. Groman, Lee Josephson, Roy A. Whitehead
-
Patent number: 4624932Abstract: A product, Astrocytin, derived from brain cancer cells growing in vivo, and the method of preparing same. Astrocytin may be complexed with an inert carrier, such as bromoacetyl cellulose, and employed in tests for brain tumors. The antibody to Astrocytin is also prepared. A complex of Astrocytin and an inert carrier may be further complexed to anti-Astrocytin.Type: GrantFiled: July 30, 1981Date of Patent: November 25, 1986Inventor: Samuel Bogoch
-
Patent number: 4599305Abstract: A method for detecting chronic myelogenous leukemia in a human comprising the step of testing a biological sample from a patient to determine the presence of a marker protein (P210) which is characterized as a c-abl protein having tyrosine kinase activity and a molecular weight of approximately 210,000. Antisera which are specific for the P210 protein are disclosed which can be used to precipitate the P210 protein to allow identification by gel electrophoresis or other technique.Type: GrantFiled: July 16, 1984Date of Patent: July 8, 1986Assignee: The Regents of the University of CaliforniaInventors: Owen N. Witte, Susan Watanabe, James Konopka
-
Patent number: 4595661Abstract: An immunoassay for assaying an antigenic substance (Ag) in a fluid. The immunoassay is the type which comprises contacting the fluid with at least one first entity selected from a group consisting of an antibody (Ab) to the Ag, a soluble, labeled antibody (L-Ab.sub.a) to the Ag, and an antibody (Ab.sub.b) to the Ag bound to a solid support (SC). The immunoassay is characterized in that the fluid is contacted with at least one additional entity selected from a group consisting of at least one different type of soluble, labeled antibody (L-Ab.sub.c) to the Ag, at least one different type of antibody (Ab.sub.d) bound to a solid carrier (SC.sub.1), and at least one different type of antibody (Ab.sub.e) to the Ag. The SC.sub.1 is selected from a group consisting of SC, at least one different solid carrier (SC.sub.2), and mixtures thereof (SC and SC.sub.2). Each type of L-Ab.sub.c, Ab.sub.d -SC.sub.1, and Ab.sub.e has a lower average affinity constant (K) for Ag than each respective K of L-Ab.sub.a, Ab.sub.Type: GrantFiled: November 18, 1983Date of Patent: June 17, 1986Assignee: Beckman Instruments, Inc.Inventors: Linda K. Cragle, Paul C. Harris, Shih-Yun Lee, Ker-Kong Tung, Morton A. Vodian
-
Patent number: 4591572Abstract: The present invention concerns an autologous precipitating antibody and the gp70 pigment-associated antigen on melanoma cells which it recognizes. The antibody is useful in detecting pigmented melanoma cells in excised specimen, serum or urine.Type: GrantFiled: April 1, 1983Date of Patent: May 27, 1986Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: M. Jules Mattes, Timothy M. Thomson, Lloyd J. Old, Kenneth O. Lloyd
-
Patent number: 4587221Abstract: The present invention relates to a method which eliminates centrifugation and decantation steps, to be performed in an automatic manner for carrying out specific binding assay tests, wherein liquid and solid phases are present.According to the invention, use is made of a specially designed device, consisting of a mixing reservoir into which is fitted snugly a mixer separator having a channel in the vertical axis of the mixer-separator. A rack holding a number of said mixing reservoirs containing the incubated reagents and analytes, capped with the mixer separators, is placed into a press-device designed to perform at a controlled rate a downward movement. The mixer separators are pushed downwards into the mixing reservoirs at a chosen rate for a preselected distance to complete the mass transport and separation operations. The separation devices are removed and either one of the separated phases can be measured in the desired analytical instrument for a quantitative or qualitative determination.Type: GrantFiled: December 30, 1983Date of Patent: May 6, 1986Assignee: Technion Research & Development Foundation, Ltd.Inventors: Michael Cais, Moshe Shimoni
-
Patent number: 4530900Abstract: The invention pertains to an improved heterogeneous enzymeimmunoassay involving the use of a reversibly soluble polymeric substance acting as the support for the antibody. In the direct method the antigen to be detected and an enzyme labeled antigen are bound by antibody which is chemically linked to the soluble polymeric substance. The polymer is rendered insoluble and removed from the test solution. After resolubilization into a solution containing substrate for the enzyme label, the assay for antigen is completed by determination of enzymatic activity. In the indirect method, the antigen to be detected and an enzyme labeled antigen are incubated with a primary antibody unattached to the polymeric substance. After addition of a second antibody which is chemically linked to the polymeric substance, the polymer is rendered insoluble and the assay is performed as in the direct method described above.Type: GrantFiled: September 13, 1982Date of Patent: July 23, 1985Assignee: Seragen Diagnostics Inc.Inventor: David L. Marshall
-
Patent number: 4529582Abstract: Group C streptococcal antibody levels in a serum sample can be determined via passive protection test in susceptible animals. Test is based on property of protective antibody in the serum sample to reduce the virulence of a group C streptococcal challenge and provides a means for detecting whether an animal (e.g. horse) is susceptible to infection by group C streptococcal organism.Type: GrantFiled: December 30, 1982Date of Patent: July 16, 1985Assignee: Miles Laboratories, Inc.Inventors: Karen K. Brown, Sharon A. Bryant
-
Patent number: 4529581Abstract: Antigenicity of streptococcal preparations useful for inducing anti-streptococcal immunity in animals can be determined using a combining power technique. Method involves incubating serial dilutions of the antigen preparation with known amounts of anti-streptococcal antiserum, thereby lessening, in serial manner, the combining power of the antiserum. The serial reaction products are then incubated with serial dilutions of streptococcal preparations having known activity and the effects of the serial reaction products on such activity are then determined by in vivo means. Those determinations can be related to a standard for determining potency of the streptococcal preparation. Assay technique is especially useful in determining potency of Streptococcus equi bacterins or bacterin derivatives.Type: GrantFiled: December 30, 1982Date of Patent: July 16, 1985Assignee: Miles Laboratories, Inc.Inventors: Karen K. Brown, Sharon A. Bryant
-
Patent number: 4522923Abstract: The present invention describes an apparatus and method for conducting immunochemical reactions in a self-contained sealed unit that requires only the addition of an unknown sample and water. The apparatus comprises a test tube with at least three chambers each containing different chemicals, including a solid sphere, and separated from each other by a water-soluble barrier.Type: GrantFiled: October 3, 1983Date of Patent: June 11, 1985Assignee: Genetic Diagnostics CorporationInventors: Alice Deutsch, Herbert Platt
-
Patent number: 4522922Abstract: Ligand having at least two determinant or binding sites is contacted with a labeled first binder, an unlabeled second binder different than the first binder and a precipitating binder specific for the second binder, with such contacting precipitating a complex of the ligand and the first and second binders to thereby separate bound labeled binder from unbound labeled binder. The bound and/or unbound labeled binder is determined as a measure of the ligand.Type: GrantFiled: April 16, 1982Date of Patent: June 11, 1985Inventors: Jose Carro, Frank de Velasco
-
Patent number: 4517288Abstract: A method for conducting a ligand assay in an inert porous medium wherein a binding material is immunologically immobilized within the medium, which includes the steps of immunologically immobilizing a binding material within a finite zone of the medium, applying an analyte to the zone containing the immobilized binding material, applying a labeled indicator to the zone which becomes immobilized within the zone in an amount which can be correlated to the amount of analyte in the zone, applying a solvent to substantially the center of the zone to chromatographically separate the unbound labeled indicator from the zone, and measuring the amount of labeled indicator remaining in the zone.Type: GrantFiled: January 23, 1981Date of Patent: May 14, 1985Assignee: American Hospital Supply Corp.Inventors: Joseph L. Giegel, Mary M. Brotherton
-
Patent number: 4514506Abstract: The invention comprises a method for the purification of a human lung tumor-associated antigen (hLTAA) specific to human lung tumors of diverse histological characteristics; serum levels of hLTAA correlate with lung tumor incidence, and appear to usefully discriminate between various stages of the malignancies. The invention further comprises an immunoassay predicated on purified hLTAA for the detection and quantitative determination of hLTAA in biological fluids, particularly blood serum, and diagnostic systems for clinical immunoassay procedures.Type: GrantFiled: January 28, 1983Date of Patent: April 30, 1985Assignee: The Government of the United States as represented by the Secretary of the Department of Health and Human ServicesInventors: James A. Braatz, Kenneth R. McIntire, Gerald L. Princler
-
Patent number: 4506009Abstract: A conjugate useful in determining the amount of antigen or antibody in a liquid sample, said conjugate having a marker, an immunoreactive component (i.e. antigen or antibody) bound to the marker and an insolubilizing binding component which is also bound to the marker. The insolubilizing binding component portion of the conjugate will react with an insolubilizing receptor to form a solid product of conjugate and receptor unless the conjugate reacts with the corresponding antigen or antibody to be analyzed in which event the conjugate will not react with the insolubilizing receptor. The conjugate will be added to a liquid sample containing an unknown amount of, for example, an antibody. A known amount of the corresponding antigen is also added which reacts with both the conjugate and antibody. After the reaction is complete, the liquid sample is contacted with the insolubilizing receptor.Type: GrantFiled: March 30, 1982Date of Patent: March 19, 1985Assignee: University of CaliforniaInventors: Howard M. Lenhoff, That T. Ngo
-
Patent number: 4504587Abstract: The antigens procollagen peptide (type (III) and procollagen peptide col 1 (type III) can be determined together immunologically by either(a) reacting a specified amount in each case of labeled procollagen peptide (type III) or procollagen peptide col 1 (type III) and a highly specific antiserum containing antibodies having affinity for both the antigens mentioned together with a sample having an unknown content of procollagen peptide (type III) and/or procollagen peptide col 1 (type III), separating off the antigen-antibody complex formed and measuring the amount of labeling in the complex and/or in the supernatant, or(b) bringing a specified amount of the highly specific antiserum to reaction with a sample having an unknown content of procollagen peptide (type III) and/or procollagen peptide col 1 (type III), fixing the unreacted amount of the antibody to procollagen peptide (type III) or procollagen peptide col 1 (type III) bound to a support, and bringing to reaction with a labeled second antibody, and thType: GrantFiled: March 11, 1983Date of Patent: March 12, 1985Assignee: Hoechst AktiengesellschaftInventors: Rupert Timpl, Dietrich Brocks, Horst Neubauer, Helmut Strecker
-
Patent number: 4478934Abstract: A method of quantative determination of adenosine by means, of competitive immunoassay based on a competitive antigen-antibody reaction. In the competitive antigen-antibody reaction, an antibody is used which is obtained from an animal which has been immunized by introduction thereto of an antigen which comprises a carrier protein bonded with 2'- and 3'-hydroxyls of the adenosine through dicarboxylic acid residues, and a labelled adenosine and 2',3'-diacyladenosine which has been produced by acylation of adenosine in the sample to be assayed or in a standard solution are caused to undergo competitive reaction for the antibody whereby it has been made possible to determine adenosine quantitatively in high sensitivity and in high accuracy.Type: GrantFiled: July 9, 1982Date of Patent: October 23, 1984Assignee: Yamasa Shoyu Kabushiki KaishaInventors: Tomokazu Sato, Michio Ui
-
Patent number: 4473652Abstract: A method for immunochemical assay of an antigen or antibody by labelling the antigen or antibody with a specific cyanine or merocyanine dye containing a carboxy group followed by effecting an immune reaction and photochemical processing thereof is provided. The amount of the antigen or antibody is measured in term of optical density of developed silver halide which is brought into contact with either the antigen-antibody reaction product or the unreacted material.This immunochemical assay method gives high detection sensitivity in a simple operation manner.Type: GrantFiled: June 22, 1983Date of Patent: September 25, 1984Assignee: Fuji Photo Film Co., Ltd.Inventors: Masaki Okazaki, Nobuhito Masuda, Yoshiro Kumano
-
Patent number: 4469796Abstract: An improvement in assaying methods involving biospecific affinity reactions, in which there are used from 2 to 4 reactants, one of which, reactant (I), is labelled with at least one analytically indicatable atom or group and is soluble in the aqueous liquid in which the biospecific affinity reaction is carried out, the reactants forming, by means of biospecific reactions, a conjugate in which labelled reactant (I) is incorporated; and in which assaying methods the analytically indicatable atom or group is assayed in the conjugate and/or in labelled reactant (I), which is not bound to the conjugate. The conjugate that has been formed or labelled reactant (I) not bound to the conjugate is bound covalently to an insoluble carrier or to an insolubilizable carrier, which latter carrier is made insoluble after the covalent binding has been carried out, whereafter the assay of the analytically indicatable atom or group is carried out.Type: GrantFiled: May 5, 1981Date of Patent: September 4, 1984Assignee: Pharmacia Diagnostics ABInventors: Rolf E. A. V. Axen, Sven O. H. Oscarsson, Per H. G. Ponterius, Jan P. E. Carlsson
-
Patent number: 4456690Abstract: The present invention relates to a method which eliminates centrifugation and decantation steps, to be performed in an automatic manner for carrying out specific binding assay tests, wherein liquid and solid phases are present.According to the invention, use is made of a specially designed device, consisting of a mixing reservoir into which is fitted snugly a mixer separator having a channel in the vertical axis of the mixer-separator. A rack holding a number of said mixing reservoirs containing the incubated reagents and analytes, capped with the mixer separators, is placed into a press-device designed to perform at a controlled rate a downward movement. The mixer separators are pushed downwards into the mixing reservoirs at a chosen rate for a preselected distance to complete the mass transport and separation operations. The separation devices are removed and either one of the separated phases can be measured in the desired analytical instrument for a quantitative or qualitative determination.Type: GrantFiled: June 29, 1982Date of Patent: June 26, 1984Assignee: Technion Research and Development Foundation, Ltd.Inventors: Michael Cais, Moshe Shimoni
-
Patent number: 4450231Abstract: An immunoassay of a specimen of a serum or the like to determine immune complexes, includes producing on a plastic base a layer of a non-proteinaceous, non-ionic polymer which will adhere to the plastic base and has the capability of absorbing immune complexes of the specimen, placing a specimen on the layer and treating the layer to produce an indication of the amount of immune complexes. The polymer may be polyethylene glycol, dextran, polyvinyl chloride, a polymeric polyol or an adduct of polyethylene glycol. Washing with conventional solutions, addition of an antihuman IgG coupled with an enzyme and addition of a substrate reactive therewith, are similar to the ELISA test, with color measurement as by spectrophotometer. Or, the addition of anti IgG-I.sup.125 and measurement by a scintillation counter may be used. The ethylene glycol may range in molecular weight from 2,000 to 20,000, although 6,000 to 8,000 is preferred.Type: GrantFiled: March 31, 1982Date of Patent: May 22, 1984Assignee: Biostar Medical Products, Inc.Inventor: Adil N. Ozkan
-
Patent number: 4429050Abstract: A method for the simultaneous immunochemical assay of trace components in a sample involving competitively reacting the antigens or antibodies in a sample and labeled antigens or labeled antibodies for limited binding sites. The labels are spectral sensitizing dyes. The reaction products are contacted with silver halide and exposed to light having wavelengths corresponding to the absorption spectra of the spectral sensitizing dyes.Type: GrantFiled: September 2, 1981Date of Patent: January 31, 1984Assignee: Fuji Photo Film Co., Ltd.Inventors: Yukio Yasuda, Nobuhito Masuda, Yuji Mihara, Masaki Okazaki, Nobuo Hiratsuka
-
Patent number: 4414324Abstract: An improved immunoassay sample determination process for determining the presence of a component of an antigen-antibody reaction in a sample is disclosed which substantially eliminates non-specific interactions between the sample and the reaction vessel wall surfaces during the antigen-antibody reaction, to thereby greatly increase the accuracy of the process. In practice, a site-deactivating medium such as an animal- or vegetable-derived total biological fluid or extract (e.g., plasma or gelatin) is covalently bound to the vessel wall surfaces for deactivation purposes. In preferred forms the process is solid-state, wherein one of the components of the antigen-antibody reaction is coupled covalently to the coating medium, and a reaction mixture fraction including the sample being determined and the other component which has been labeled, for instance by means of a colorimetrically active enzyme.Type: GrantFiled: April 9, 1981Date of Patent: November 8, 1983Assignee: BMA Laboratory Services, Inc.Inventor: Robert L. Stout
-
Patent number: 4405711Abstract: In a method of assay for a trace component such as antigen, antibody or enzyme utilizing immunochemical reaction or enzyme reaction in combination with photographic detection system comprising measuring optical density of a silver image formed in proportion to the antigen, antibody or enzyme to be measured, a novel analysis sheet comprising a support having provided thereon, in succession, a water absorbing layer and a silver halide emulsion layer is employed. The analysis sheet essentially increases the amount of water absorbed so that the analysis sheet is extremely effective for improving detection sensitivity.Type: GrantFiled: September 2, 1981Date of Patent: September 20, 1983Assignee: Fuji Photo Film Co., Ltd.Inventors: Nobuhito Masuda, Shigeru Nagatomo, Yuji Mihara
-
Patent number: 4404289Abstract: In an immunochemical measurement method of an antigen or antibody which comprises competitively reacting an antigen or antibody labelled with spectral sensitizer and an antigen or antibody to be measured, bringing either the reaction product of immune reaction or the unreacted component into contact with silver halide, exposing the same to light having a wavelength which the spectral sensitizer absorbs, developing the exposed silver, and, measuring optical density of the thus formed silver image and/or colored dye, the contact with silver halide is performed in the presence of a specific hydrazine compound. Thus, detection sensitivity is markedly improved.Type: GrantFiled: September 2, 1981Date of Patent: September 13, 1983Assignee: Fuji Photo Film Co., Ltd.Inventors: Nobuhito Masuda, Shigeru Nagatomo, Yuji Mihara
-
Patent number: 4373932Abstract: Processes, reagents and test kits for the qualitative and/or quantitative determination of an immunochemically reactive component, in which one or more labelled components are used, that are obtained by direct or indirect coupling of such a component or components to particles of an aqueous dispersion of a hydrophobic dye or pigment, or of polymer nuclei coated with such a dye or pigment.During the reaction or after an adequate reaction time the nature and/or the quantity of the dye is determined in the test medium, or optionally after a separation of the bound and free labelled components in one of the fractions.Type: GrantFiled: January 2, 1981Date of Patent: February 15, 1983Assignee: Akzona IncorporatedInventors: Thomas C. J. Gribnau, Frits Roeles, Johannes H. W. Leuvering
-
Patent number: 4371514Abstract: Pterin derivatives are described having the formula (I) ##STR1## wherein R represents a hydroxyphenyl group, a radioiodinated hydroxyphenyl group, a tyraminocarbonyl group, a radioiodinated tyraminocarbonyl group, a proteinocarbonyl group or a carboxy group; Q represents a straight or branched chain alkylene group having 1 to 6 carbon atoms; and R.sub.6 and R.sub.7 each represents a hydrogen, an alkyl group having from 1 to 6 carbon atoms, a hydroxyalkyl group having from 1 to 6 carbon atoms; and a radioimmunoassay method is described using a radioiodinated 4-hydroxy-2-tyraminopteridine derivative or a radioiodinated 4-hydroxy-2-tyraminocarbonylalkylaminopteridine derivative as the tracer.Type: GrantFiled: July 7, 1980Date of Patent: February 1, 1983Assignee: Daiichi Radioisotope Laboratories, Ltd.Inventors: Toshiharu Nagatsu, Takeshi Kato, Tokio Yamaguchi, Miki Akino, Sadao Matsuura, Takashi Sugimoto